Drug repurposing gives existing medicines a second life, but only when the business model clears the path. At Orfenix, we structure Intellectual Property strategically to align investor incentives, guarantee patient access, and deliver sustainable impact. Discover how our IP approach protects innovation and connects commercial potential with public health outcomes.

Orfenix proudly supports the development of guanabenz for Vanishing White Matter—a rare, progressive brain disease in children. Learn how repurposed drugs and dedicated research offer hope.

PXE is a rare disease with serious impact on daily life. We spoke with Heleen van Loenen from the Dutch PXE patient organisation about patient experiences—and why Orfenix is working to develop a treatment.

Pharmaceutical innovation thrives on a balance between exclusivity and accessibility. Limited-time commercial exclusivity incentivizes research while ensuring broader patient access over time. Discover how these mechanisms shape the future of equitable healthcare.

Drug repurposing – also called drug repositioning or drug reprofiling – is the identification of new therapeutic uses for existing medicinal products.

Orphan drugs, which are developed to treat rare diseases, face unique challenges in clinical trials. While the incentives for developing orphan drugs, such as tax credits and market exclusivity, have encouraged pharmaceutical companies to invest in this area, the clinical trial process remains fraught with difficulties.

The European Medicines Agency (EMA) scientific advice procedure is designed to enhance communication between sponsors and regulators, streamlining the development of high-quality medicinal products. Preparing a clear and well-structured briefing document is key to obtaining meaningful feedback.

Drug development is a long, expensive, and risky process. It takes an average of 10-15 years and requires a multi billion investment to bring a new drug from the laboratory to patients.

Orfenix welcomes a recently published report of the Medicines Patent Pool, in partnership with Boston Consulting Group, shows how voluntary licensing brings both improved access to medicines, in particular in low and middle-income countries and economic benefits to the companies doing the out-licensing.